Feistritzer Hans-Josef, Reinstadler Sebastian Johannes, Klug Gert, Reindl Martin, Wöhrer Sebastian, Brenner Christoph, Mayr Agnes, Mair Johannes, Metzler Bernhard
University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Anichstraße 35, A-6020, Innsbruck, Austria.
Department of Radiology, Medical University of Innsbruck, Anichstraße 35, A-6020, Innsbruck, Austria.
BMC Cardiovasc Disord. 2016 Nov 28;16(1):239. doi: 10.1186/s12872-016-0415-z.
Presence of microvascular obstruction (MVO) derived from cardiac magnetic resonance (CMR) imaging is among the strongest outcome predictors after ST-segment elevation myocardial infarction (STEMI). We aimed to investigate the comparative predictive values of different biomarkers for the occurrence of MVO in a large cohort of reperfused STEMI patients.
This study included 128 STEMI patients. CMR imaging was performed within the first week after infarction to assess infarct characteristics, including MVO. Admission and peak concentrations of high-sensitivity cardiac troponin T (hs-cTnT), creatine kinase (CK), N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), lactate dehydrogenase (LDH), aspartate transaminase (AST) and alanine transaminase (ALT) were measured.
MVO was detected in 69 patients (54%). hs-cTnT, CK, hs-CRP, LDH, AST and ALT peak concentrations showed similar prognostic value for the prediction of MVO (area under the curve (AUC) = 0.77, 0.77, 0.68, 0.79, 0.78 and 0.73, all p > 0.05), whereas the prognostic utility of NT-proBNP was weakly lower (AUC = 0.64, p < 0.05). Combination of these biomarkers did not increase predictive utility compared to hs-cTnT alone (p = 0.349).
hs-cTnT, CK, hs-CRP, LDH, AST and ALT peak concentrations provided similar prognostic value for the prediction of MVO. The prognostic utility of NT-proBNP was lower. Combining these biomarkers could not further improve predictive utility compared to hs-cTnT alone.
源自心脏磁共振(CMR)成像的微血管阻塞(MVO)是ST段抬高型心肌梗死(STEMI)后最强的预后预测指标之一。我们旨在研究在一大群再灌注STEMI患者中,不同生物标志物对MVO发生的比较预测价值。
本研究纳入了128例STEMI患者。在梗死发生后的第一周内进行CMR成像,以评估梗死特征,包括MVO。测量入院时和峰值浓度的高敏心肌肌钙蛋白T(hs-cTnT)、肌酸激酶(CK)、N末端B型利钠肽原(NT-proBNP)、高敏C反应蛋白(hs-CRP)、乳酸脱氢酶(LDH)、天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)。
69例患者(54%)检测到MVO。hs-cTnT、CK、hs-CRP、LDH、AST和ALT的峰值浓度在预测MVO方面显示出相似的预后价值(曲线下面积(AUC)分别为0.77、0.77、0.68、0.79、0.78和0.73,均p>0.05),而NT-proBNP的预后效用略低(AUC=0.64,p<0.05)。与单独使用hs-cTnT相比,这些生物标志物的组合并未增加预测效用(p=0.349)。
hs-cTnT、CK、hs-CRP、LDH、AST和ALT的峰值浓度在预测MVO方面具有相似的预后价值。NT-proBNP的预后效用较低。与单独使用hs-cTnT相比,联合这些生物标志物并不能进一步提高预测效用。